Inside the SLE Pipeline: Patient Enrollment Complete in Phase 2b Trial of Alumis Inc.’s Oral TYK2 Inhibitor
Patient enrollment is complete in Alumis Inc.’s LUMUS Phase 2b trial of ESK-001, an oral tyrosine kinase 2 (TYK2) inhibitor, in systemic lupus erythematosus (SLE).